Publication details

Management of Moderate to Severe Plaque Psoriasis with Brodalumab in Daily Practice: Real-World Evidence from the LIBERO Study in the Czech Republic

Authors

GKALPAKIOTIS Spyridon KOJANOVA Martina FIALOVA Jorga CETKOVSKA Petra VAŠKŮ Vladimír VANTUCHOVA Yvetta MACHOVCOVA Alena GKALPAKIOTI Petra HRDA Pavla ARENBERGER Petr

Year of publication 2024
Type Article in Periodical
Magazine / Source DERMATOLOGY AND THERAPY
MU Faculty or unit

Faculty of Medicine

Citation
Web https://link.springer.com/article/10.1007/s13555-023-01066-z
Doi http://dx.doi.org/10.1007/s13555-023-01066-z
Keywords Brodalumab; Biological therapy; LIBERO; Non-interventional study; Plaque psoriasis; Real-world evidence
Description IntroductionPsoriasis is a chronic, immune-mediated inflammatory skin disease. Despite the availability of several therapies, many patients affected by this disease remain untreated, do not have adequate response, or suffer from treatment-related toxic effects. It has been shown that the interleukin (IL)-17 pathway plays a key role in the immunopathogenesis of psoriasis. Brodalumab, the first human monoclonal IgG2 antibody that selectively binds to subunit A of the human IL-17 receptor, blocking interactions with a number of cytokines of the IL-17 family, has confirmed fast onset of action, high complete clearance rates, and sustained efficacy. Nevertheless, there is only a limited amount of published real-world evidence (RWE) data.MethodsThis was an open-label, multicenter, real-world, prospective, non-interventional, non-controlled (single-arm) observational study (LIBERO-CZ) assessing the management of moderate to severe psoriasis with brodalumab in daily practice for up to 52 weeks of treatment.ResultsFifty-four patients (70.4% male, mean age 46.9 +/- 13.4 years, weight 95.6 +/- 22.7 kg, disease duration 18.6 +/- 12.7 years) were enrolled and included in the final analysis. Forty-nine of the patients completed the study and five discontinued prematurely; 51.8% of all the enrolled patients were biologic-naive. At baseline, 28% patients were classified as severe (psoriasis area severity index (PASI) >= 20). Overall, the mean PASI decreased by 15.6 from 16.1 (+/- 5.0) at baseline to 0.5 (+/- 1.2) at the last visit. The primary endpoint of an absolute PASI <= 3 at week 12 (as observed analysis) was achieved by 95.9% of patients. The static Physician's Global Assessment (sPGA) success (defined as clear = 0 and almost clear = 1) at week 52 was achieved by 92.1% of patients. PASI 75, PASI 90, and PASI 100 were achieved by 98.0%, 87.8%, and 75.5% of patients, respectively, after approximately 52 weeks of treatment. The study also recorded very positive results concerning patient-reported outcomes.ConclusionsLIBERO-CZ confirms the fast onset and high clearance rates of brodalumab in real life in both biologic-naive and biologic-experienced patients.

You are running an old browser version. We recommend updating your browser to its latest version.

More info